



PATENT APPLICATION
File No: 02-22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Penny J. Thompson, Paul O. Sheppard
Serial No. : 10/680,755
Group Art Unit : 1646
Examiner : Chandra, G.
Filed : October 7, 2003
For : USES OF HUMAN ZVEN ANTAGONISTS
Date Submitted : April 11, 2006

AMENDMENT FEE TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED


<u>Claim Type</u>	<u>Total Claims After Amendment</u>	<u>Highest No. Covered by Previous Payments</u>	<u>Extra</u>	<u>Extra Rate</u>	<u>Fees Paid</u>
Total	<u>10</u>	-36	<u>0</u> x	<input type="checkbox"/> \$25 <input type="checkbox"/> \$50	\$0
Independent	<u>2</u>	-13	<u>0</u> x	<input type="checkbox"/> \$100 <input type="checkbox"/> \$200	\$0

Total: \$0

Please charge any required fee to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Robyn Adams
Registration No. 44,495



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Penny J. Thompson, Paul O. Sheppard
Serial No. : 10/680,755
Filed : October 7, 2003
For : USES OF HUMAN ZVEN ANTAGONISTS

Examiner : Chandra, G.
Art Unit : 1646
Docket No. : 02-22
Date : April 11, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

The Restriction Requirement mailed March 24, 2006 has been received and reviewed.

In response to the Restriction Requirement dated March 24, 2006, please amend the above-identified patent application as follows:

Response to Restriction Requirement begins on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 4 of this paper.

Response to Restriction Requirement:

The Restriction Requirement sets forth a restriction requirement under 35 USC §121. Applicants were requested to elect one of six designated groups as briefly noted below:

I. Claims 1-22, drawn to a method of reducing inflammation in the intestine of a mammal comprising administering a Zven1 antagonist, classified in class 514, subclass 1.

II. Claims 1-22, drawn to a method of reducing inflammation in the intestine of a mammal comprising administering a Zven2 antagonist, classified in class 514, subclass 1.

III. Claims 23, 26, 27, 30, drawn to a method of detecting inflammatory bowel disease in a biological sample comprising screening the sample for a polynucleotide sequence, classified in class 435, subclass 7.1.

IV. Claims 24-25, 25-29, drawn to a method of detecting inflammatory bowel disease in a biological sample comprising screening the sample for a polypeptide sequence, classified in class 435, subclass 7.1.

V. Claims 31-34, drawn to a method of treating inflammatory bowel disease in a mammal comprising administering the mammal a polypeptide, classified in class 514, subclass 2.

VI. Claims 35-36, drawn to a method of treating inflammatory bowel disease in a mammal comprising administering the mammal a polynucleotide, classified in class 514, subclass 44.

In response to the Requirement for Restriction Election, Applicants elect Group III, claims 23, 26, 27, 30, drawn to a method of detecting inflammatory bowel disease in a biological sample comprising screening the sample for a polynucleotide sequence, classified in class 435, subclass 7.1. Within this Group III, Applicants have added new claims 37-44. In response to the further restriction of Group III, Applicants elect the nucleic acid sequence of SEQ ID NO: 1.